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Objectives This was a phase II trial to assess flurpiridaz F 18 for safety and compare its diagnostic performance for positron
emission tomography (PET) myocardial perfusion imaging (MPI) with Tc-99m single-photon emission computed
tomography (SPECT) MPI with regard to image quality, interpretative certainty, defect magnitude, and detection
of coronary artery disease (CAD) (50% stenosis) on invasive coronary angiography (ICA).
Background In pre-clinical and phase I studies, flurpiridaz F 18 has shown characteristics of an essentially ideal MPI tracer.
Methods One hundred forty-three patients from 21 centers underwent rest-stress PET and Tc-99m SPECT MPI. Eighty-six pa-
tients underwent ICA, and 39 had low-likelihood of CAD. Images were scored by 3 independent, blinded readers.
Results A higher percentage of images were rated as excellent/good on PET versus SPECT on stress (99.2% vs. 88.5%, p 
0.01) and rest (96.9% vs. 66.4, p  0.01) images. Diagnostic certainty of interpretation (percentage of cases with
definitely abnormal/normal interpretation) was higher for PET versus SPECT (90.8% vs. 70.9%, p  0.01). In 86 pa-
tients who underwent ICA, sensitivity of PET was higher than SPECT (78.8% vs. 61.5%, respectively, p  0.02). Speci-
ficity was not significantly different (PET: 76.5% vs. SPECT: 73.5%). Receiver-operating characteristic curve area was
0.82  0.05 for PET and 0.70  0.06 for SPECT (p  0.04). Normalcy rate was 89.7% with PET and 97.4% with
SPECT (p  NS). In patients with CAD on ICA, the magnitude of reversible defects was greater with PET than SPECT
(p  0.008). Extensive safety assessment revealed that flurpiridaz F 18 was safe in this cohort.
Conclusions In this phase 2 trial, PET MPI with flurpiridaz F 18 was safe and superior to SPECT MPI for image quality, inter-
pretative certainty, and overall CAD diagnosis. (J Am Coll Cardiol 2013;61:469–77) © 2013 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.022Over the past 4 decades, radionuclide myocardial perfusion
imaging (MPI) has become the mainstay of stress imaging
for the evaluation of patients with suspected or known
coronary artery disease (CAD). The method offers objective
means of detecting stress-induced perfusion defects due to
hemodynamically significant coronary stenoses, thereby
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sequence, mild reductions in max-
imal achievable coronary flow
might not result in corresponding
decreases in myocardial tracer up-
take. Furthermore, these agents
have lower spatial resolution than
the positron emission tomography
(PET) agents fluorine-18 (F-18)
and nitrogen-13. These limita-
tions have long been the impetus
toward the development of radio-
pharmaceuticals that would have
superior uptake versus flow rela-
tionships at peak flow rates as well
as higher image resolution. Short-
lived cyclotron-produced PET
MPI agents, including oxygen-15
water and nitrogen-13 ammonia,
have excellent flow versus uptake
characteristics at high flow rates
(10,11); however, these tracers are
not practical for widespread clini-
cal use due to the requirement that
they be used in very close proxim-
ity to medical cyclotrons.
Flurpiridaz F 18, labeled with
positron-emitting isotope F-18,
has recently been developed as an
MPI radiopharmaceutical for use
with PET (12–17). In pre-clinical as well as phase I studies,
flurpiridaz F 18 has been shown to have essentially linear
myocardial uptake throughout the range of flow (13,17). It
also has high myocardial retention, low background in
adjacent organs, and other characteristics that suggest it
might be close to an ideal myocardial perfusion tracer
(7,15,16). The purpose of this phase II trial was to assess the
clinical safety of flurpiridaz F 18 and to compare the
diagnostic performance of this agent with Tc-99m MPI
tracers with respect to image quality, certainty of interpre-
tation, magnitude of reversible perfusion defects, and diag-
nostic efficacy for detection of CAD.
Methods
Study population. Patients were eligible for the study if
they were referred for clinically indicated single-photon
emission computed tomography (SPECT) MPI or if they
had undergone invasive coronary angiography (ICA) with-
out percutaneous coronary intervention (PCI) within 60
days. Patients were recruited from 21 centers in the United
States. All potential child-bearing female patients under-
went pregnancy testing within 24 h before receiving the
PET tracer. Patients were not eligible for the study if they
were 18 years of age, had PCI or coronary artery bypass
Abbreviations
and Acronyms
AE  adverse event
CAD  coronary artery
disease
CT  computed
tomography
F-18  fluorine-18
ICA  invasive coronary
angiography
MI  myocardial infarction
MPI  myocardial perfusion
imaging
PCI  percutaneous
coronary intervention
PET  positron emission
tomography
QCA  quantitative
coronary angiography
ROC  receiver-operating
characteristic
SDS  summed different
score
SPECT  single-photon
emission computed
tomography
SRS  summed rest score
SSS  summed stress
scoregrafting within 6 months before either PET or SPECT, had flnonischemic cardiomyopathy or an ejection fraction of
35%, or were unable to undergo exercise or pharmacolog-
ical stress testing. The study was approved by the institu-
tional review boards of all participating centers, and all
patients provided written informed consent.
Study design. All patients underwent SPECT MPI within
90 days before or 60 days after flurpiridaz F 18 PET MPI.
If SPECT MPI had been performed before enrollment on
an accepted SPECT camera, repeat SPECT examination
was not performed. In those without such a SPECT study,
both SPECT and PET scans were performed for purposes
of the research trial during the study. In patients who had
ICA, the ICA was performed within 60 days of PET MPI.
All patients were evaluated for flurpiridaz F 18 safety.
Patients who underwent any imaging were evaluated for
image quality and diagnostic certainty. Patients who under-
went ICA were evaluated for test performance characteris-
tics, whereas those who did not undergo ICA but who could
be classified as low CAD likelihood were evaluated for
normalcy rate.
Stress testing protocols. Stress tests were performed with
either exercise or pharmacological stress according to Amer-
ican Society of Nuclear Cardiology Guidelines (18), with
the intention to have the same stress test for both proce-
dures. Exercise testing was performed with a standard Bruce
exercise treadmill protocol, and the radiopharmaceutical was
injected at the same time-point during the SPECT and
PET procedures. Pharmacological stress tests were con-
ducted with adenosine, regadenoson, or dipyridamole. Pa-
tients were instructed to have no caffeine intake for 24 h
before pharmacological stress testing and were taking the
same cardiac active medications at the time of both SPECT
and PET studies.
SPECT imaging protocol. Tc-99m agents were used for all
SPECT imaging (73 Tc-99m sestamibi and 35 Tc-99m
tetrofosmin in 1-day protocol; 10 Tc-99m sestamibi and 6
Tc-99m tetrofosmin in 2-day protocol). There were 19 cases
performed with the rest Tl-201 and stress Tc-99m dual isotope
MPI protocol. All PET and SPECT cameras used in the
study were subjected to and passed quality control proce-
dures reviewed by the core laboratory for purposes of the
study. The SPECT scanning was performed with standard
American Society of Nuclear Cardiology Guidelines with
either rest/stress or a stress/rest protocol (18).
PET imaging protocol. All PET imaging was performed
at rest and stress in accordance with the pre-defined study
protocol with either PET/computed tomography (CT)
systems (n  140) or dedicated PET scanners (n  3). All
ET cameras used in the study were subjected to quality
ontrol procedures for the purpose of this study. For
ET/CT, attenuation correction CT scans were obtained
efore rest and stress examinations. For dedicated PET,
ransmission scans for attenuation correction scans were
erformed with a radioisotope source. Imaging was per-
ormed in list-mode. Rest imaging began at the time of the
urpiridaz F 18 injection and was continuously acquired
rw
m
a
S
471JACC Vol. 61, No. 4, 2013 Berman et al.
January 29, 2013:469–77 Flurpiridaz F 18 PET: Phase II Studyover 20 min. Stress dosing began 73.4  12.1 min after rest
studies in patients undergoing exercise stress and 52.9 
11.2 min after rest studies in patients undergoing pharma-
cological stress testing. One patient undergoing exercise
stress had rest and stress procedures completed on different
dates and was not included in the aforementioned summary
of the rest/stress dose interval. In the pharmacological stress
group, 2.91  0.70 mCi of flurpiridaz F 18 was injected at
est, and 6.76  1.78 mCi was injected at stress. In the
exercise group, these doses were 1.93 0.37 mCi and 6.48
1.23 mCi, respectively. The mean effective radiation dose to
the patients from these injections is estimated to be approx-
imately 6.4 mSv and 4.8 mSv for the pharmacological and
exercise rest/stress protocols, respectively (14).
MPI image interpretation. All images were interpreted in
an imaging core laboratory (Les Services Nucmed, Mon-
treal, Canada). Both overall qualitative diagnosis and semi-
quantitative 17-segment with 5-point (0  normal, 4 
absent tracer uptake) scoring were employed in the inde-
pendent, blinded read by 3 expert readers who were expe-
rienced in both SPECT and PET MPI interpretation. The
same 3 readers interpreted all of the SPECT and PET
studies in independent cross-over reading sessions. The
readers were blinded to which study was being performed,
the type of stress, patient sex, and all clinical data as well as
to the reading of other readers. Image quality was classified
as excellent, good, fair, poor, or uninterpretable. Certainty
of overall interpretation was classified definitely normal,
probably normal, probably abnormal, and definitely
abnormal.
For the purpose of assessing diagnostic efficacy, each
blinded reader rated the rest/stress perfusion and gated
images as normal, ischemic, ischemic and scar, or scar. A
patient was considered MPI negative if the rating was
normal. Summed stress scores (SSS), summed rest scores
(SRS), and summed difference scores (SDS) were calcu-
lated by the core laboratory (18). A patient was consid-
ered to have a reversible defect when the SDS was 2.
For patients who underwent attenuation-corrected
SPECT or both supine and prone SPECT acquisitions,
the readers assessed only the non–attenuation-corrected,
supine SPECT images.
Coronary angiography interpretation. All coronary an-
giograms were interpreted with quantitative coronary an-
giography (QCA) in a coronary angiography core laboratory
(Perfuse, Boston, Massachusetts) blinded to the clinical or
imaging results. A coronary stenosis was considered present
when there was 50% diameter stenosis in any epicardial
coronary artery. The presence of 1 or more coronary
stenoses defined the presence of significant CAD. The core
laboratory had no knowledge of history of myocardial
infarction (MI). Presence or absence of wall motion abnor-
mality was not considered in interpreting the presence or
absence of CAD. The determination of the presence or
absence of CAD was strictly related to coronary stenosis in
the native coronary arteries. Arteries with patent stents wereclassified as no significant CAD, regardless of evidence of
prior MI. Arteries with patent bypass grafts but native
coronary stenosis were classified as significant CAD.
Safety analysis. Safety assessments included blood and
urine testing as well as clinical monitoring for possible
adverse events (AEs). Patients were monitored for 30 min
after the rest injection and for 60 min after the stress
injections for clinical symptoms, vital signs, and electrocar-
diogram changes. They were followed for 2 weeks after the
drug administration for AEs. All AEs were adjudicated by
the site principal investigator, including whether they were
considered to be related to the drug or to the stress test. A
serious AE was defined as any AE considered life threat-
ening, resulting in death, requiring in-patient hospital stay,
or persistent or significant disability/incapacity.
Statistical analysis. Continuous variables were expressed
as mean (or median) and range or SDs. Paired continuous
variables that were not normally distributed were compared
with the Wilcoxon signed rank test for matched pairs or the
paired t test if normally distributed. Categorical variables
ere expressed as frequencies. Primary diagnostic efficacy
easures were sensitivity and specificity and were assessed
fter blinded and independent reads of PET MPI and
PECT MPI data with ICA as the truth standard (n 86).
Efficacy estimates for PET MPI and SPECT MPI were
compared individually with a 2-sided paired test of
proportions (McNemar test) at 5% level of significance.
Normalcy rate was determined in the patients with a low
likelihood of CAD and no ICA and was calculated as
percentage of patients with normal/probably normal
studies. Analysis of diagnostic efficacy was performed by
reader as well as with majority rule, and the results of
majority rule analysis were used in the overall efficacy
analysis. Where majority rule was used for the compari-
son between PET and SPECT MPI, the estimate was
obtained with the rating obtained by 2 of 3 blinded
readers for each patient. The analysis of diagnostic
certainty used a modified majority rule in which the
median rating was used when 3 readers have 3 different
ratings. Summaries and comparisons of SRS, SSS, and
SDS measures similarly used the median of the results of
3 blinded readers. Receiver-operating characteristic
(ROC) curve analysis was performed in the 86 patients
undergoing ICA with the comparison of area under ROC
between PET MPI and SPECT MPI diagnostic efficacy.
The area under ROC and confidence intervals used the
empirical approach developed by DeLong et al. (19).
The interreader agreement between 3 blinded readers was
estimated by comparison of dichotomized ratings (normal/
abnormal) and was presented with kappa and percentage
agreement. Intrareader agreement for each of the readers
was performed by randomizing 10% of the repeat images in
the blinded read and was estimated with kappa and per-
centage agreement.
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Patient population characteristics. There were 143 pa-
tients enrolled into the overall study population, 107 men,
and the mean age was 62.5 years (Table 1). The mean body
mass index was 28.3. There were 108 white, 3 Asian, 16
African American individuals, and 16 who classified them-
selves as “other” race/ethnicity. Patients were stratified into
3 pre-test CAD likelihood categories: low (n  45);
intermediate (n  68); and high (n  30) (18,20), the latter
including patients with known CAD. In the angiographic
cohort (n  86), 52 patients had significant CAD by QCA,
and 34 patients had no significant CAD or normal coronary
arteriograms. In this cohort, 70 patients had SPECT studies
performed before PET and ICA; 15 patients had ICA
before PET and SPECT studies, and 1 patient had PET
study completed before ICA and SPECT study. In this
cohort, 22 had prior MI, 42 had prior revascularizations,
and 43 had either prior MI or revascularization. Figure 1
depicts the manner in which the 143 patients were enrolled
and evaluated. Eleven patients were excluded for the reasons
listed, leaving 132 patients who had both SPECT MPI and
PET MPI studies evaluable for image quality and diagnostic
certainty comparison. Seven patients of the 132 with an
intermediate or high likelihood of CAD did not undergo
ICA. The remaining 125 patients were evaluable for diag-
nostic efficacy and included 86 with ICA evaluated for
sensitivity and specificity for angiographic CAD and 39
Patient CharacteristicsTable 1 Patient Characteristics
Efficacy Population
(n  125)
Total
(N  143)
Age, yrs 62.3 (29–85) 62.5 (29–88)
Age 65 yrs 59 (47.2) 67 (46.9)
Race
White 97 (77.6) 108 (75.5)
Asian 3 (2.4) 3 (2.1)
African American 13 (10.4) 16 (11.2)
Other 12 (9.6) 16 (11.2)
Sex
Male 92 (73.6) 107 (74.8)
Female 33 (26.4) 36 (25.2)
BMI, kg/m2 28.6 (18–42) 28.3 (17–42)
Prior MI 22 (17.6) 26 (18.2)
CABG 14 (11.2) 17 (11.9)
PCI 28 (22.4) 31 (21.7)
CABG or PCI 42 (33.6) 48 (33.6)
Prior MI or revascularization 43 (34.4) 50 (40.0)
Family history of CAD 56 (44.8) 66 (46.2)
Diabetes 29 (23.2) 32 (22.4)
Tobacco use 53 (42.4) 60 (42.0)
Pre-test likelihood of CAD
Low 41 (32.8) 45 (31.5)
Intermediate 58 (46.4) 68 (47.6)
High 26 (20.8) 30 (21.0)
Values are mean (min–max) or n (%).u
BMI bodymass index; CABG coronary artery bypass grafting; CAD coronary artery disease;
MI  myocardial infarction; PCI  percutaneous coronary intervention.patients with a low likelihood of CAD assessed for nor-
malcy rate.
Stress flurpiridaz F 18 PET MPI was performed with
either exercise (n  76) or adenosine (n  67) stress. For
PECT MPI, pharmacological stress was conducted with
denosine (n  44), regadenoson (n  7), or dipyridamole
n 10). A total of 5 of 143 patients had different stress test
ypes between 2 MPI procedures.
linical safety. Among the 132 patients in the safety
opulation, 2 patients reported a total of 3 serious AEs
dizziness, hypertension, and knee effusion) that were
udged to be unrelated to study drug. Sixty-one patients
42.7% of the 143) reported 108 AEs. Thirty-six of these 61
atients received pharmacological stress with a total of 75
Es, and the remaining 25 patients received exercise stress
ith a total of 33 AEs. One hundred of the 108 AEs were
onsidered not related to study drug. Of the remaining 8
Es judged as possibly or probably related to the study
rug, all were of either mild or moderate severity and
esolved without any complications. Five of these 8 were
lso judged as possibly or probably related to the stress test
tself. The remaining 3 of the 8 patients had the following:
ransient hypertension, mild cough, and a metallic taste.
he AEs associated with the Tc-99m and Tl-201 injections
ere not obtained. There was no evidence of clinically
elevant flurpiridaz F 18 effect on QT interval in this study.
n independent data-monitoring committee that reviewed
afety data at regular intervals did not raise any significant
afety concerns.
mage quality. Among the 132 patients assessed for image
uality, image quality was judged to be superior with
urpiridaz F 18 for both stress and rest (Fig. 2). On the
tress studies, 99.2% were considered to be good or excellent
ith flurpiridaz F 18 versus 88.5% with Tc-99m (p 0.01).
n the rest studies, image quality was considered to be good
r excellent in 96.9% with flurpiridaz F 18 versus 66.4%
ith Tc-99m (p  0.01). Excellent image quality alone was
bserved on stress images in 80.9% with flurpiridaz F 18
nd in 24.4% with Tc-99m (p  0.01) and on rest studies
n 69.5% with flurpiridaz F 18 versus 7.6% with Tc-99m
p  0.01).
iagnostic certainty. In the overall efficacy population of
32 patients, diagnostic certainty was greater with
urpiridaz F 18 than with Tc-99m (Fig. 3). Certainty of
nterpretation was classified as definitely normal or defi-
itely abnormal in 90.8% of patients by flurpiridaz F 18 and
n 70.9% of patients by Tc-99m (p  0.01), with approxi-
ately a 3-fold reduction in the patients in the probably
ormal and probably abnormal groups.
etection of CAD. In the 86 patients who underwent
CA and thus had a truth standard for coronary stenosis, 52
ad significant CAD on ICA. The sensitivity of PET was
igher than that of SPECT (78.8% vs. 61.5%, respectively,
 0.02). The specificity was not significantly different
76.5% for PET vs. 73.5% for SPECT) (Fig. 4). The area
nder the ROC curve was 0.82 0.05 for PET and 0.70
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a low likelihood of CAD, the normalcy rate was 89.7% with
PET and 97.4% with SPECT (p  NS).
Magnitude of stress and rest perfusion defect. The SSS
and SRS scores in the patients who underwent ICA are
shown in Table 2 according to the number of vessels
abnormal on ICA. In patients with 1- and 2-vessel stenosis,
the median SSS was greater with PET than with SPECT.
Magnitude and frequency of reversible perfusion
defect. The magnitude of reversible perfusion defect on
PET and SPECT in the patients who underwent ICA is
Figure 1 Summary of Patient Enrollment and Disposition
CAD  coronary artery disease; ICA  invasive coronary angiography; MPI  myoc
SPECT  single-photon emission computed tomography.
Figure 2 Image Quality Comparing Flurpiridaz F 18
PET MPI and SPECT MPI (N  132)
N  132. Shown are the proportion of patients with excellent or good
image quality (left) and excellent only (right). Abbreviations as in Figure 1.shown in Tables 3 and 4. In the patients with coronary
stenosis (Table 3), the mean SDS and the proportion of
patients with SDS 2 was higher with PET than SPECT
as interpreted by each reader. In the patients without
coronary stenosis (Table 4), the mean SDS and the propor-
tion of patients with SDS 2 was not significantly different
between the 2 MPI modalities for any of the readers.
Reader agreement. Interreader agreement rates for pres-
ence of abnormality were 90% in PET MPI between 3
readers with kappa values of 0.80 between readers. In-
trareader agreement rates were slightly lower for SPECT
MPI (80%) and kappa values of at least 0.60. Intrareader
perfusion imaging; PET  positron emission tomography;
Figure 3 Diagnostic Certainty Comparing
Flurpiridaz F 18 PET MPI and SPECT MPI
N  132. Def.  definitely; Prob.  probably; other abbreviations as in Figure 1.ardial
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modalities.
Case examples. Examples of PET and SPECT images
from a patient with no coronary stenosis on ICA are shown
in Figure 6 and from a patient with left anterior descending
oronary artery stenosis in Figure 7.
iscussion
his is the first multicenter clinical trial comparing the
iagnostic performance of flurpiridaz F 18, a new myocar-
ial perfusion PET tracer with conventional Tc-99m
PECT. Interpreted with rigorous core laboratory image
nalysis, the findings show that flurpiridaz F 18 can detect
emodynamically significant obstructive CAD with greater
ensitivity, superior image quality, and with greater diag-
ostic certainty compared with SPECT MPI. The radiation
oses associated with the flurpiridaz F 18 injections were
pproximately 2 lower than those associated with standard
est/stress Tc-99m SPECT MPI protocols. Importantly, in
Figure 4 Sensitivity and Specificity Comparing Flurpiridaz
F 18 PET MPI and SPECT MPI for Detection of CAD
Abbreviations as in Figure 1.
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Figure 5 Receiver-Operating Characteristics Analysis
PET  positron emission tomography;
SPECT  single-photon emission computed tomography.Satients with significant coronary stenosis, the frequency
nd magnitude of reversible perfusion defect was greater
ith PET than SPECT. The extensive safety assessment
onducted in this phase II study revealed that flurpiridaz F
8 was safe and well-tolerated in this study.
mage quality and diagnostic certainty. Variation of im-
ge quality and image interpretation has been considered
ne of the limitations of conventional SPECT MPI. In this
tudy, image quality and diagnostic certainty were both
igher with flurpiridaz F 18 PET than with SPECT. Image
uality was good-to-excellent in a greater proportion of
ET than SPECT scans and excellent in a far greater
roportion of patients, both at stress and at rest. This
uperior image quality was associated with a higher diag-
ostic certainty with flurpiridaz F 18 by independent read-
rs. The improved image quality and diagnostic certainty are
ikely due to the greater conspicuity of perfusion defects,
mproved resolution associated with F-18 PET, as well as
he improved diagnostic certainty associated with the use of
ET compared with SPECT and the use of attenuation
orrection for the PET studies (21). Of note, interreader
greement rates were high with both PET and SPECT and
ere higher with the PET examinations.
ensitivity and specificity for detection of CAD and
agnitude of perfusion defects. In this study we show
hat flurpiridaz F 18 PET was associated with improved
ensitivity when compared with SPECT, with specificity
imilar to SPECT. Improved diagnostic accuracy was con-
rmed by a significantly greater receiver operating charac-
eristics curve area for flurpiridaz F 18 PET compared with
PECT. Several factors might explain this improved sensi-
Summary of Median SSS and SRS Among Readersby Number of Vessels With Coronary StenosisTable 2 Summary of Median SSS and SRS Among Readersby Number of Vessels With Coronary Stenosis
SSS SRS
Vessels
Involved (n) PET SPECT p Value PET SPECT p Value
0 (n 34) 2.3 3.6 NS 1.0 1.5 NS
1 (n 16) 9.7 6.5 0.05 3.0 2.8 NS
2 (n 19) 10.5 5.1 0.05 1.3 2.2 NS
3 (n 17) 13.1 14.3 NS 2.6 3.8 NS
PET  positron emission tomography; SPECT  single-photon emission computed tomography;
RS  summed rest score; SSS  summed stress score.
Summary of SDS in PatientsWith Angi graphy-Posi ve ResultsTable 3 ummary of SDS in PatientsWith Angiography-Positive Results
Reader Statistic PET SPECT p Value
1 Mean SD 8.9 7.98 4.8 5.61 0.01
SDS 2, n (%) 37 (71.2) 28 (53.8) 0.06
2 Mean SD 9.4 7.51 5.7 6.51 0.01
SDS 2, n (%) 36 (69.2) 26 (50.0) 0.02
3 Mean SD 6.8 5.75 4.1 4.75 0.02
SDS 2, n (%) 37 (71.2) 26 (50) 0.01
N  52.
PET  positron emission tomography; SPECT  single-photon emission computed tomography;
DS  summed different score.
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January 29, 2013:469–77 Flurpiridaz F 18 PET: Phase II Studytivity for CAD detection, including the higher extraction
fraction of the tracer, the improved spatial resolution of
PET versus SPECT, and the use of attenuation correction
in the PET studies.
Magnitude of perfusion defects. The magnitude of stress
and reversible perfusion defect with flurpiridaz F 18 PET
was nearly double that of the Tc-99m SPECT studies in
patients with coronary stenosis. The increased magnitude of
perfusion defects in patients with angiographic stenosis was
seen with each of the individual readers, as was the propor-
tion of patients with disease-manifesting significant
amounts of ischemia (SDS 2). The magnitude of perfu-
sion defect was not different between the tracers in the
patients without significant stenosis.
Potential explanations for greater stress perfusion defect
magnitude and higher sensitivity for CAD detection.
Flurpiridaz F 18 exhibits near-linear myocardial extraction
and retention across the range of achievable myocardial
Figure 6 FLUR PET and MIBI SPECT
Images From a 75-Year-Old Man
Flurpiridaz F 18 (FLUR) PET (top) and Tc-99m sestamibi (MIBI) SPECT (bottom)
images from a 75-year-old man, with a body mass index of 32.6 and no CAD
on ICA. The FLUR images were interpreted as normal, whereas the MIBI
images were interpreted as probably abnormal with a possible reversible defect
in the basal inferior wall. Abbreviations as in Figure 1.
Summary of SDS in PatientsWith Angi graphy-Negative ResultsTable 4 ummary of SDS in PatientsWith Angiography-Negative Results
Reader Statistic PET SPECT p Value
1 Mean SD 2.4 5.26 3.1 5.50 0.24
SDS 2, n (%) 8 (23.5) 14 (41.2) 0.11
2 Mean SD 1.2 3.57 2.7 5.34 0.13
SDS 2, n (%) 4 (11.8) 9 (26.5) 0.06
3 Mean SD 1.4 2.85 1.6 3.97 0.91
SDS 2, n (%) 8 (23.5) 6 (17.6) 0.48
N  34.
Abbreviations as in Table 3.blood flow (17). In contrast, a “roll off” of extraction at high
myocardial perfusion rates has been reported for the com-
monly used SPECT agents Tc-99m-sestamibi, Tc-99m-
tetrofosmin, and Tl-201 (4–7) as well as for the generator-
produced PET agent Rb-82 (8,9). The higher extraction
fraction of flurpiridaz F 18 compared with the SPECT
tracers (17) at high flow rates is likely to be an important
factor explaining the differences in magnitude of perfusion
defect as well as higher sensitivity for perfusion defect
detection observed in this study. During maximal exercise or
with maximal coronary vasodilation, areas of the myocar-
dium supplied by vessels without stenosis demonstrate
myocardial perfusion rates in the range of 3 to 4 ml/min/g
(8,22). These are perfusion rates at which a marked differ-
ence in uptake between tracers with high extraction fraction
and low extraction fraction has been observed (4,5,17). By
contrast, areas of the myocardium supplied by vessels with
high-grade coronary stenosis have lower levels of maximal
myocardial perfusion, which would manifest similar uptake
between tracers with high- and low-extraction fractions (4).
These factors would result in a greater magnitude of a stress
perfusion defect with the more highly extracted agent. In
regions supplied by a vessel with mild coronary stenosis,
maximal myocardial perfusion would be expected to be only
slightly reduced compared with those supplied by vessels
without stenosis. This mild reduction in myocardial perfu-
sion might be detectable with the more highly extracted
Figure 7 FLUR PET and MIBI SPECT
Images From an 82-Year-Old Man
The FLUR PET (top) and MIBI SPECT (bottom) images from an 82-year-old man
with shortness of breath and an occluded native proximal left anterior descend-
ing (LAD) coronary artery and an occluded left internal mammary graft to the
LAD and no other significant native CAD. The FLUR images show a severe
reversible perfusion defect throughout the territory of the occluded proximal
LAD, whereas the MIBI images show only a moderate perfusion defect in the
distal LAD territory (apical slices). Abbreviations as in Figures 1 and 6.tracer but might be insufficient to be detected by radiophar-
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contributing to the higher sensitivity observed with
flurpiridaz F 18 than with the Tc-99m SPECT agents in
this study. Improved spatial resolution of PET compared
with SPECT and the use of attenuation correction with the
PET studies might have contributed to the higher accuracy
of flurpiridaz F 18 PET studies. In patients who had
attenuation-corrected SPECT or both supine and prone
SPECT imaging, only the supine SPECT imaging was
assessed. Of note, the greater magnitude of reversible
perfusion defect noted with flurpiridaz F 18 PET raises the
possibility that reassessment of the threshold for ischemia
used clinically to consider a study as indicating potential
benefit from revascularization might have to be recalibrated
in future studies.
Study limitations. This study has several limitations. Not
all patients underwent ICA. The overall sensitivity of
SPECT MPI in this study was generally lower than that
reported in published clinical reports. These results are
consistent with recent well-controlled SPECT MPI studies
that implemented independent blinded read with multiple
readers and have been conducted for regulatory purposes
(23,24). Several factors might have led to this low sensitivity
in both imaging modalities. Patient selection is likely to
have been a significant contributor. Because the majority of
the patients underwent both SPECT and PET before ICA,
it is possible that patients with greater amounts of ischemia
by SPECT or with greater symptoms might have been more
likely to have been not referred for this trial, due to the
desire of the clinician or the patient not to have an
additional stress test before ICA. Because patients with
recent ICA but no coronary intervention were not excluded
from the trial, patients undergoing the PET examinations
after ICA are more likely to have had angiographic lesions
of only borderline significance at ICA, thus potentially
reducing the sensitivity of both SPECT and PET. Addi-
tionally, in individuals with prior MI, the use of 50%
stenosis QCA criteria might have led to a misclassification
of patients, because fixed perfusion defects in these patients
would be expected even if the infarct-related artery had been
successfully opened at a prior PCI (i.e., if vessels in patients
with prior PCI did not show 50% stenosis, the patients
ere categorized as normal, even if the vessels were supply-
ng a region of MI). In this regard, 48 patients had
ndergone prior revascularization 6 months before the
PI studies, and 26 had prior MI. The determination of
he presence or absence of CAD was based on coronary
tenosis in the native coronary arteries; arteries with patent
ypass grafts but native coronary stenosis were classified as
ignificant CAD. The acceptance of patients into this trial
ho completed SPECT before ICA and had the PET study
fter ICA might have biased the population toward lower
pecificity by SPECT. The use of the 50% stenosis by
CA as the criterion for abnormality might have included
atients as abnormal for the truth standard who do not have
ow-limiting stenosis, falsely lowering the sensitivity ofstenosis detection. The absence of flow-limiting stenosis in
a substantial proportion of patients with 50% stenosis has
been documented in studies comparing angiographic steno-
sis with abnormalities of coronary flow reserve as measured
invasively by fractional flow reserve (24). Higher spatial
resolution associated with PET compared with SPECT
imaging methods might have contributed to the results.
Attenuation correction was applied in the PET studies and
not in the SPECT studies. Although this is the largest
group of patients to be studied with this novel perfusion
agent, the number of patients is still relatively small, and this
might affect the statistical significance of our results.
Conclusions
Flurpiridaz F 18 PET, when compared with Tc-99m
SPECT, has better image quality and shows higher diag-
nostic certainty. In patients with coronary stenosis by ICA,
flurpiridaz F 18 PET manifests higher sensitivity than
SPECT for detection of patients with coronary stenosis as
well as greater magnitude of ischemia. These findings
suggest that this new tracer might significantly improve the
assessment of patients with radionuclide MPI compared
with the standard SPECT MPI methods.
Acknowledgement
The authors thank Mr. Mark Hyun, CNMT, for his
technical assistance in the preparation of this manuscript.
Reprint requests and correspondence: Dr. Daniel S. Berman,
Departments of Imaging and Medicine, Cedars-Sinai Heart In-
stitute, 8700 Beverly Boulevard, Room 1258, Los Angeles, Cali-
fornia 90048. E-mail: bermand@cshs.org.
REFERENCES
1. Berman DS, Hachamovitch R, Shaw LJ. Nuclear cardiology. In:
Fuster V, O’Rourke R, Walsh R, Poole-Wilson P, editors. Hurst’s the
Heart, 12th edition. New York, NY: McGraw Hill, 2008:544–76.
2. Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and
scar on the therapeutic benefit derived from myocardial revasculariza-
tion vs. medical therapy among patients undergoing stress-rest myo-
cardial perfusion scintigraphy. Eur Heart J 2011;32:1012–24.
3. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/
AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for
cardiac radionuclide imaging: a report of the American College of
Cardiology Foundation Appropriate Use Criteria Task Force, the
American Society of Nuclear Cardiology, the American College of
Radiology, the American Heart Association, the American Society of
Echocardiography, the Society of Cardiovascular Computed Tomog-
raphy, the Society for Cardiovascular Magnetic Resonance, and the
Society of Nuclear Medicine. J Am Coll Cardiol 2009;53:2201–29.
4. Glover DK, Ruiz M, Edwards NC, et al. Comparison between 201Tl
and 99mTc sestamibi uptake during adenosine-induced vasodilation as
a function of coronary stenosis severity. Circulation 1995;91:813–20.
5. Glover DK, Ruiz M, Yang JY, Smith WH, Watson DD, Beller GA.
Myocardial 99mTc-tetrofosmin uptake during adenosine-induced va-
sodilatation with either a critical or mild coronary stenosis: comparison
with 201Tl and regional myocardial blood flow. Circulation 1997;96:
2332–8.
6. Glover DK, Gropler RJ. Journey to find the ideal PET flow tracer for
clinical use: are we there yet? J Nucl Cardiol 2007;14:765–8.
7. Maddahi J. Properties of an ideal PET perfusion tracer: new PET
tracer cases and data. J Nucl Cardiol 2012;19:S30–37.
477JACC Vol. 61, No. 4, 2013 Berman et al.
January 29, 2013:469–77 Flurpiridaz F 18 PET: Phase II Study8. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp
RA. Quantification of myocardial blood flow with 82Rb dynamic PET
imaging. Eur J Nucl Med Mol Imaging 2007;34:1765–74.
9. Mullani NA, Goldstein RA, Gould KL, et al. Myocardial perfusion
with rubidium-82. I. Measurement of extraction fraction and flow with
external detectors. J Nucl Med 1983;24:898–906.
10. Schelbert HR, Phelps ME, Huang SC, et al. N-13 ammonia as an
indicator of myocardial blood flow. Circulation 1981;63:1259–72.
11. Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN.
Noninvasive quantitation of myocardial blood flow in human subjects
with oxygen-15-labeled water and positron emission tomography.
J Am Coll Cardiol 1989;14:639–52.
12. Huisman MC, Higuchi T, Reder S, et al. Initial characterization of an
18F-labeled myocardial perfusion tracer. J Nucl Med 2008;49:630–6.
13. Nekolla SG, Reder S, Saraste A, et al. Evaluation of the novel
myocardial perfusion positron-emission tomography tracer 18F-BMS-
747158-02: comparison to 13N-ammonia and validation with micro-
spheres in a pig model. Circulation 2009;119:2333–42.
14. Maddahi J BF, Huang S-C, Czernin J, Schelbert H, Zhu Q. Phase 1
rest-stress study of F-18 labeled BMS747158 myocardial perfusion
PET tracer: human safety, dosimetry, biodistribution, and myocardial
imaging characteristics. J Nucl Med 2009;50:1.
15. Maddahi J, Czernin J, Lazewatsky J, et al. Phase I, first-in-human
study of BMS747158, a novel 18F-labeled tracer for myocardial
perfusion PET: dosimetry, biodistribution, safety, and imaging char-
acteristics after a single injection at rest. J Nucl Med 2011;52:1490–8.
16. Yalamanchili P, Wexler E, Hayes M, et al. Mechanism of uptake and
retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET
myocardial imaging agent. J Nucl Cardiol 2007;14:782–8.17. Yu M, Guaraldi MT, Mistry M, et al. BMS-747158-02: a novel PET
myocardial perfusion imaging agent. J Nucl Cardiol 2007;14:789–98.18. Holly TA, Abbott BG, Al-Mallah M, et al., American Society of
Nuclear Cardiology. Single photon-emission computed tomography.
J Nucl Cardiol 2010;17:941–73.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas
under two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics 1988;44:837–45.
20. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline
update for the management of patients with chronic stable angina—
summary article: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
(Committee on the Management of Patients With Chronic Stable
Angina). J Am Coll Cardiol 2003;41:159–68.
21. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of
rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison
with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006;13:
24–33.
22. Slomka PJ, Alexanderson E, Jacome R, et al. Comparison of clinical
tools for measurements of regional stress and rest myocardial blood
flow assessed with 13N-ammonia PET/CT. J Nucl Med 2012;53:
171–81.
23. Senior R, Monaghan M, Main ML, et al. Detection of coronary
artery disease with perfusion stress echocardiography using a novel
ultrasound imaging agent: two Phase 3 international trials in
comparison with radionuclide perfusion imaging. Eur J Echocar-
diogr 2009;10:26 –35.
24. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici
PG. Relation between myocardial blood flow and the severity of
coronary-artery stenosis. N Engl J Med 1994;330:1782–8.Key Words: flurpiridaz F 18 y myocardial perfusion y SPECT.
